DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The ...

The CONNECT trial found greater A1C reductions and more time in target glucose range among adults using continuous glucose monitoring.

DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal ...

DexCom, Inc. announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the ...

Scientists tested a wearable blood sugar monitor on adults who weren't taking insulin. The results revealed a measurable ...

DexCom (DXCM) shares spiked on Thursday after The New England Journal of Medicine published results from the company's CONNECT trial for its G7 insulin pump in type 2 diabetes, supporting potential ...

The new 2026 data highlights an urgent opportunity for people with Type 2 diabetes: closing the gap between CGM's proven, ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...